Offer - Urjas Oil for just ₹ 1
Calgrow is an allopathic medicine The correct dosage of Calgrow depends on the patient's age, gender, and medical history. This information has been provided in detail in the dosage section.
Calgrow is used to treat the following -
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Is the use of Calgrow safe for pregnant women?
Pregnant women can take Calgrow safely.
Is the use of Calgrow safe during breastfeeding?
Calgrow does not show any side effects in breastfeeding women.
What is the effect of Calgrow on the Kidneys?
Calgrow does not damage the kidneys.
What is the effect of Calgrow on the Liver?
Calgrow does not damage the liver.
What is the effect of Calgrow on the Heart?
Calgrow is completely safe for the heart.
Calgrow should not be taken with following medicines due to severe side effects it may cause to patients -
Severe
Moderate
If you are suffering from any of the following diseases, you should not take Calgrow unless your doctor advises you to do so -
Is this Calgrow habit forming or addictive?
No, you will not get addicted to Calgrow.
Interaction between Food and Calgrow
It is safe to take Calgrow with food.
Interaction between Alcohol and Calgrow
Information about the interaction of Calgrow and alcohol is not currently available because this topic has not been researched yet.
This medicine data has been created by -
References
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 1276-1279
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Pentetate zinc trisodium injection (Zn-DTPA)
KD Tripathi. [link]. Seventh Edition. New Delhi, India: Jaypee Brothers Medical Publishers; 2013: Page No 680